DU-176b shows promise in orthopaedic setting
This article was originally published in Scrip
Executive Summary
New Phase II data for Daiichi-Sankyo's anticoagulant DU-176b show that the oral direct Factor Xa inhibitor reduced the incidence of venous thromboembolism (VTE) in patients undergoing total hip replacement surgery compared with dalteparin.